ASH2L CRISPR/Cas9 KO Plasmid (m): sc-423846
- Target species: mouse
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- ASH2L CRISPR/Cas9 Knockout (KO) Plasmid (m) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the ASH2L genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: ASH2L Antibody (2046D2a): sc-81184
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
ASH2L CRISPR/Cas9 KO Plasmid (m) | sc-423846 | 20 µg | $397.00 |
Overview
Ash2l encodes ASH2L, a core component of the SET1/MLL histone H3K4 methyltransferase complexes that regulate chromatin state and transcriptional programs. Through control of H3K4 methylation, ASH2L contributes to RNA polymerase II–dependent gene expression, enhancer activity, and epigenetic maintenance of cell identity during development and differentiation. ASH2L-dependent chromatin regulation intersects with pathways governing cell-cycle progression, DNA damage responses, and lineage specification, making it relevant to studies of stem cell biology and hematopoiesis. Dysregulated ASH2L or MLL/SET1 complex activity has been implicated in oncogenic transcriptional states and developmental abnormalities, supporting its use as a mechanistic node in epigenetics-focused disease models.
ASH2L CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Ash2l gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Ash2l together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Ash2l open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish ASH2L protein expression.
This CRISPR knockout system enables efficient generation of Ash2l-deficient cell models for investigation of ASH2L signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting Ash2l exon(s) critical for ASH2L function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple Ash2l genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by ASH2L CRISPR/Cas9 KO Plasmid (m) and ASH2L CRISPR/Cas9 KO Plasmid (m2) target distinct sites within the Ash2l locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by ASH2L HDR Plasmid (m) and ASH2L HDR Plasmid (m2) contain a puromycin resistance cassette and an RFP reporter flanked by Ash2l homology arms to support homology-directed repair at defined Ash2l target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.